In the phase III PADA-1 trial presented at 2021 San Antonio Breast Cancer Symposium, it was observed that switching from an aromatase inhibitor plus palbociclib to fulvestrant and palbociclib upon early identification of the ESR1 mutation in plasma-before disease progression- the median PFS was doubled. This evidence concerns the gene ESR1 and breast cancer.